Optimizing Treatment Selection for Patients with FLT3-ITD AML
Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Read More
Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML
Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.
Read More
Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.
Read More
An Introduction to Biomarker Testing in Acute Myeloid Leukemia
Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.
Read More
An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia
Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.
Read More
The Potential Future Impact of CAR T Cell Therapy in Adult ALL
Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.
Read More
The ZUMA-3 Trial: Clinical Endpoints
Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.
Read More
The ZUMA-3 Trial: Efficacy and Safety Results
Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.
Read More
The ZUMA-3 Trial: Study Design and Patient Population
Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.
Read More
Using MRD to Monitor Therapeutic Response in ALL
Key experts in hematology oncology discuss the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.
Read More
The Evolving Treatment Landscape for ALL
Eunice Wang, MD and Bijal Shah, MD, MS, begin with an overview of novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.
Read More
Future Treatment Landscape of AML
Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Read More
Maintenance Therapy Post-Transplant in AML
Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.
Read More
Use of APR-246 and Oral HMAs in AML
Read More
Use of Omidubicel Therapy in Hematologic Malignancies
Read More
BMT CTN 1102 Study in High-Risk MDS
Read More
Novel Targets and Biomarkers in AML
Read More
IDH1/2-Mutated Treatment-Naïve AML
Read More
BCL2 Inhibition in AML: VIALE-A Study
Read More
Type 1/2 FLT3 Inhibitors in AML
Read More
Role of Dual Targeted Therapy in AML
Read More
Sequencing of FLT3 Inhibitors in AML
Read More
Management of AML: FLT3 Inhibitors and BCL2 Inhibitors
Read More
Role of FLT3 Inhibitors in Chemo-Ineligible AML
Read More
MRD Monitoring in FLT3 ITD AML
Read More
Prognostic Significance of IDH Mutations in AML
Read More
FLT3 Testing for Treatment of AML
Read More
Molecular Testing in Community Practices
Read More